57 results about "Hippocampal neuron" patented technology

The invention belongs to the field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition with an anti-depression effect, which is prepared from the following medicinal materials by weight: 6g of pericarpium citri reticulatae viride, 6g of pericarpium citri reticulatae, 6g of radix paeoniae alba, 6g of thunberg fritillary bulb, 4.5 g of rhizoma alismatis, 4.5 g of fried gardenia and 4.5 g of moutan bark. The composition regulates functions of hypothalamus-pituitary-adrenal axis (HPA axis) and repairs hippocampal neurons and relieves symptoms such as pleasant sensation loss and behavioral despair of depression patients by relieving qi stagnation, clearing heat, cooling blood, promoting diuresis and reducing phlegm. Experiments prove that the traditional Chinese medicine composition can remarkably improve the sweet water preference rate of depression rats, shorten the forced swimming immobility time, reduce the levels of CRH, ACTH and CORT of plasma and improve pathological injuries of hippocampus tissues. The composition adopts medicinal and edible medicinal materials, is small in side effect and high in safety, and can be prepared into an oral preparation for treating depression.

The invention discloses construction and application of a Primrose syndrome non-human animal model, and belongs to the technical field of animal models and disease research. According to the invention, through a CRISPR / Cas9 technology, a codon CAC for coding 596th histidine in a No.14 exon of a mouse Zbtb20 gene is subjected to site-directed mutagenesis into CGC for coding arginine, and a hybrid mouse model for simulating pathogenic point mutation (p.H596R) of human Primrose syndrome is constructed. The model can stably reproduce key clinical phenotypes of the Primrose syndrome, including overgrowth after adult, serum IGF-1 rise, memory dysfunction and anxiety behaviors, and shows abnormal hippocampal neuronal development and synaptic transfer related pathways and the like. The invention provides an important experimental tool for deeply revealing the pathological mechanism of Primrose syndrome, developing drug screening and treatment intervention research and the like.

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The application discloses expression regulation of alpha-synuclein and application thereof. The alpha-synuclein inhibitor is used for preparing a medicine, and the obtained medicine has the effects of preventing and treating anxiety caused by social isolation. Experiments prove that after the alpha-synuclein inhibitor is administered, the anxiety behavior of a model animal in a social isolation environment can be improved, and the alpha-synuclein inhibitor has a treatment effect on anxiety caused by social isolation. The alpha-synuclein inhibitor is selected from the following: 1) an ASO targeting SNCA mRNA coding alpha-synuclein; 2) a small-molecule compound targeting SNCA mRNA coding alpha-synuclein; or 3) an AAV interfering with the expression level of alpha-synuclein in a ventral hippocampal neuron.

The invention discloses application of a miR-5588-3p inhibitor, and belongs to the technical field of biological medicines. Researches find that the expression of miR-5588-3p in the plasma of an epileptic is abnormally increased. The miR-5588-3p inhibitor is given 72 hours before the tree shrew epilepsy model is constructed, so that the attack level, the convulsion rate and the death rate of the epilepsy tree shrew can be effectively reduced, and the brain pathological injury of the epilepsy tree shrew can be relieved. The miR-5588-3p inhibitor disclosed by the invention is used for preparing a medicine for treating epilepsy, and the nucleotide sequence of the miR-5588-3p inhibitor is as follows: GCUGGCAUUAGUGGGACUU. According to the present invention, the convulsion rate and the death rate of the epilepsy tree shrew can be well reduced, the matrix incubation period and the convulsion incubation period of the epilepsy tree shrew can be effectively prolonged, the convulsion duration of the epilepsy tree shrew can be shortened, the attack level of the epilepsy tree shrew can be effectively reduced, and the miR-5588-3p inhibitor can significantly reduce the hippocampal neuron damage.

The invention relates to the technical field of biological medicines, and discloses application of a ZBP1 inhibitor in preparation of a medicine for treating cognitive impairment caused by plastics. Research finds that exposure of a specific dose of nano plastic can activate a ZBP1 signal channel in an organism and promote assembly of a pan-apoptosis small body compound, so that pan-apoptosis cascade reaction with pyroptosis, apoptosis and necrosis characteristics is triggered, and finally hippocampal neuron damage, dysfunction and learning and memory ability decline are caused. Further research shows that expression of key protein of pan-apoptosis can be remarkably inhibited through local injection of the ZBP1 inhibitor to the hippocampus, cognitive function impairment induced by nano-plastics is effectively improved, and the key effect of ZBP1 serving as a core factor in the regulation and control process is defined. Based on the discovery, the ZBP1 inhibitor can be used for preparing the medicine for treating the plastic pollution related cognitive impairment, and a brand new treatment strategy is provided for clinical intervention of the diseases.

The application discloses an IGFBP-2 derived polypeptide and application thereof in preparation of an antidepressant, and relates to the technical field of biological medicines. The amino acid sequence of the polypeptide is Pro-Lys-Lys-Leu-Arg-Pro, the N terminal of which is acetylated and the C terminal of which is amidated, and the amino acid sequence is shown as SEQ ID NO:1. The polypeptide has a small molecular weight, can easily penetrate the blood-brain barrier, and has good stability after terminal modification. Animal experiments prove that the polypeptide can significantly improve the depressive behavior of Shank3 gene knockout mice, including improving the spatial cognitive ability, enhancing the social interaction and curiosity, and relieving the anxiety behavior. Cell experiments prove that the polypeptide can significantly improve the viability of hippocampal neuron cells from Shank3 gene knockout mice, and up-regulate the expression level of synaptic plasticity related proteins GluA1 and SYN1. The polypeptide can be prepared by a chemical synthesis method, has low cost, and can be used for preparing a medicine for preventing or treating depression (especially depression related to Shank3 gene mutation).

The application discloses application of TESC as an Alzheimer's disease prevention and treatment target and relates to the field of biological medicines. A TESC overexpression (TESC-OE) hippocampal neuron cell line is constructed through lentivirus transfection, and the result shows that TESC-OE has the ability to resist A beta-induced neuron apoptosis and synapse damage. A TESC overexpression model in the hippocampus of a mouse is constructed through stereotactic injection of an adeno-associated virus, and the result shows that the hippocampal gray matter volume in the brain of the TESC-OE mouse is significantly larger than that of a wild type mouse. A beta stereotactic modeling is performed on the basis of TESC overexpression in the hippocampus, and the result shows that the TESC-OE mouse can significantly resist A beta-induced hippocampal atrophy, learning and memory dysfunction and impaired synaptic plasticity. Immunoblotting analysis reveals the molecular mechanism that TESC can increase the expression of anti-apoptotic genes in the hippocampus and reduce the expression of pro-apoptotic genes to exert a neuroprotective effect.

The application belongs to the technical field of medicine, and particularly relates to a muscone derivative, a preparation method and application thereof. The muscone derivative cyclopentadecanedione monoxime has obvious advantages over muscone and other derivatives in improving the MCAO rat mNSS score, microcirculation blood flow, reducing the cerebral infarction rate, the cortical and hippocampal neuron necrosis rate, and the brain water content, and increasing the SOD and CAT contents of the rat brain tissue which are abnormally reduced due to ischemia, and is a potential effective drug for cerebral ischemia-reperfusion injury.

The application relates to the technical field of medicines, in particular to application of glycyrrhiza chalcone A in preparation of medicines for treating depression. The application experiment shows that the glycyrrhiza chalcone A can significantly improve the CUMS-induced depression-like behavior of mice, reduce the hippocampal neuron damage, inhibit the neuroinflammatory reaction, and restore the 5-HT level, and the anti-depression mechanism may be closely related to multiple mechanisms such as down-regulation of MAPK / JNK path activity, inhibition of inflammatory factor expression and neurotransmitter regulation.

The invention discloses application of a rhizoma acori graminei extract in preparation of a medicine for inhibiting nerve cell iron deposition and ferroptosis. In vitro and in vivo levels, the invention reveals that ATR reduces iron deposition and inhibits hippocampal neuron ferroptosis by activating Nrf2 / GPX4 axis, finally improves the pharmacological mechanism of AD cognitive expression, and preliminarily characterizes the main active components of ATR. And a new strategy direction and a material basis are provided for AD treatment.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The present application mainly relates to the separation and identification and application of active ingredients in traditional Chinese medicine, and specifically discloses a separation and purification of a steroidal saponin compound in Allii Macrostemonis Bulbus. According to the physical and chemical properties and high-resolution electrospray mass spectrometry (HR-ESI-MS), one-dimensional / two-dimensional nuclear magnetic resonance spectroscopy (1D- / 2D-NMR) and other spectral technologies, the structure of the compound is identified, the structure is analyzed and the molecular formula is determined, and finally named as Allii Macrostemonis Bulbus saponin U. The pharmacological activity of Allii Macrostemonis Bulbus saponin U is studied through in vitro cell experiments, and it is found that Allii Macrostemonis Bulbus saponin U significantly improves the cell viability of mouse hippocampal neurons after glutamate treatment, has good neuroprotective activity, and can be used for the preparation and application of anti-nerve injury drugs.

The present invention relates to a composition for enhancing memory and preventing, ameliorating or treating cognitive impairment, comprising, as an active ingredient, a complex of Atractylodes macrocephala and Rumex acetosa extracts. The complex of Atractylodes macrocephala and Rumex acetosa extracts not only promotes CREB phosphorylation in hippocampal neurons, but also has a cytoprotective effect in brain neuronal cell lines, affects synapse remodeling at neuronal terminals that occurs during long-term potentiation (LTP), thereby increasing protein expression levels of synaptic remodeling factors and neuroplastic factors, and has been confirmed to improve short-term / long-term memory ability in behavioral evaluation of animal models, and thus can be effectively used as a health functional food, a medicine, or a feed additive, for enhancing memory and preventing, ameliorating or treating cognitive impairment.

The invention provides a traditional Chinese medicine composition for treating Parkinson's depression and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-10 parts of radix acanthopanacis semticosi and 1-10 parts of bulbus lilii. The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: taking the acanthopanax and the lily, adding water to soak, heating, refluxing and extracting, and combining filtrate to obtain the traditional Chinese medicine composition. Animal experiments find that the acanthopanax-lily traditional Chinese medicine composition has a good treatment effect on Parkinson depression for the first time, and can remarkably improve dyskinesia and depression symptoms, regulate neurotransmitter disorder, relieve damage to nigra and hippocampal neurons and reduce the level of inflammatory factors in serum. After being taken for a long time, the traditional Chinese medicine composition disclosed by the invention can improve depression and life quality, slow down the progress of Parkinson disease and reduce the use of Parkinson drugs.

The invention relates to the technical field of bioactive peptides, in particular to application of sipunculus nudus polypeptide in preparation of a neuroprotective drug. According to the specific technical scheme, firstly, sipunculus nudus oligopeptide is obtained through enzymolysis and an ultrafiltration membrane separation technology, the sipunculus nudus oligopeptide is separated and purified through sephadex chromatography, and on the basis of a high-glucose-induced mouse hippocampal neuron HT22 cell damage model, the collected components are separated and purified to obtain the sipunculus nudus oligopeptide. The neuroprotective effects of the sipunculus nudus oligopeptide and the separated components thereof are deeply discussed, and then the components in the sipunculus nudus oligopeptide are further separated and purified and subjected to mass spectrum peptide sequence identification by adopting reverse-phase high performance liquid chromatography. Experimental results show that the three components separated from the sipunculus nudus oligopeptide through sephadex chromatography can effectively improve the cell activity of HT22 cells after high glucose damage, and accumulation of ROS (reactive oxygen species) in the cells and occurrence of apoptosis are remarkably reduced.

The invention relates to the technical field of medicines, in particular to an iridium-kaempferol complex as well as a preparation method and application thereof. One Ir (Cp *) Cl2 structure in [Ir (Cp *) Cl2] 2 is substituted by one C15H10O6 to prepare the iridium-kaempferol complex, an Ir (III) center is combined with a kaempferol ligand for the first time, the metal organic complex Ir-Kae which not only utilizes the stability of the Ir (III) complex but also utilizes the pharmacological activity of kaempferol is developed, and through the synergistic effect of multiple mechanisms such as oxidation resistance, inflammation resistance and neuroprotection, the metal organic complex Ir-Kae can be used for preparing the metal organic complex. The spinal cord injury can be effectively treated at multiple target points. The Ir-Kae has a remarkable free radical scavenging capability, can effectively reduce the level of active oxygen in cells and organisms, realizes remarkable oxidation resistance and oxidative stress resistance, can improve the living and death degree of damaged hippocampal neurons, promotes neuronal repair, and has a remarkable anti-aging effect on hippocampal neurons. The nerve injury and the spinal cord injury are effectively treated, and a new direction is provided for assistant treatment of the spinal cord injury medicine.

The invention provides a new application of L-theanine in improvement of acute plateau hypoxia tolerance (viability), and finds and verifies that L-theanine can significantly improve the survival rate of mice in an acute hypobaric hypoxia environment and also can relieve brain tissue injury and body oxidative stress injury induced by plateau hypobaric hypoxia for the first time. And the generation of brain energy is promoted. In addition, in an in-vitro cell model, the L-theanine can also effectively improve hypoxia injury of the cobalt chloride induced hippocampal neuron cell line HT22. The invention provides a natural and safe active substance capable of improving the plateau hypoxia tolerance of an organism, provides a scientific basis for research and development of a series of acute physiological and pathological reactions caused by plateau hypoxia, and has a significant application value.

The invention provides application of a probiotic-fructo-oligosaccharide-lycium ruthenicum microecological preparation for targeted hippocampal neuron repair in neuroprotection and a composite product, and relates to the technical field of microorganisms. The probiotic oligosaccharide composition provided by the invention comprises lycium ruthenicum powder, fructo-oligosaccharide and compound probiotic powder, the compound probiotic powder comprises plant lactobacillus, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis, and the probiotic composition provided by the invention can significantly improve the neuron morphology and arrangement of a hippocampus area of a model group; the neuron damage is reduced.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for improving cognitive impairment in coronary heart disease and its use. The raw materials of the composition include the following components: Alpinia oxyphylla, Lycium barbarum, Fructus schizonepetae, Lotus seed core, Panax ginseng, Ligusticum chuanxiong, and Paeonia lactiflora. The composition of the present invention can improve cardiac function and structure after acute myocardial ischemia in coronary heart disease, reduce the area of ​​ischemic myocardial infarction, alleviate myocardial cell damage and myocardial fibrosis, alleviate damage to hippocampal neurons and ultrastructural changes, and improve learning and memory functions and cognitive behavioral performance.

The present invention relates to the field of treat age-related cognitive declines. In this study, the inventors report that GPR158, which localizes at the PC, is required for OCN- dependent autophagy induction in hippocampal neurons. Consistently, the mobilization of key autophagy players by OCN in hippocampal neurons requires core PC-proteins. In aged hippocampi, neuronal PC present an abnormal morphology, correlated with a reduction of the major core ciliary proteins levels. Conversely, restoration of their levels in aged hippocampi is sufficient to improve autophagy and cognitive deficits. Lastly, they show that core PC-proteins are required to integrate the rejuvenating effects of OCN in the hippocampus, thereby ameliorating age-related cognitive deficits. Altogether, these findings demonstrate a new paradigm for the neuron / systemic milieu communication and significantly advance our understanding of the regulatory mechanism mediating the rejuvenating effects of the pro-youth blood factor, OCN, in hippocampal neurons. This study also provides the foundation for novel therapeutic strategies to treat age-related cognitive decline, as well as neurological deficits in ciliopathies. Thus, the present invention relates to an activator of the primary cilia (PC) for use in the restoration and / or improvement of cognitive functions in a subject in need thereof.

The invention belongs to the technical field of chemistry, and particularly relates to an artificial synthesis method and application of a compound theanine diglucoside TFG. Theanine-fructosyl-glucose (TFG) is a Maillard reaction product, has obvious antioxidant activity, and is not systematically studied at present, so that the antioxidant activity of the theanine-fructosyl-glucose (TFG) can be obviously improved, and the antioxidant activity of the theanine-fructosyl-glucose (TFG) can be obviously improved. The invention provides an efficient artificial synthesis method of the compound TFG, the synthesis cost is reduced, a material basis is provided for subsequent research, and the method has the characteristics of economy, high efficiency, simplicity in operation, safety and the like, and is suitable for industrial production. Subsequently, activity screening of HT22 mouse hippocampal neuronal cells and HUVEC human vascular endothelial cells in vitro proves that the compound TFG can remarkably relieve cell oxidative damage induced by hydrogen peroxide (H2O2). Based on the synergistic protection effect of the TFG on neurons and vascular endothelial systems, the TFG is suitable for developing antioxidant drugs for treating Alzheimer's disease.

The invention discloses a medicinal and edible composition for delaying cognitive and memory function decline of old people, which comprises a fructus piperis longi extract, a radix asparagi extract and sodium hyaluronate, and is combined with highland barley, common turnip, maca, D-psicose and other active substances to prepare the medicinal and edible composition for delaying cognitive and memory function decline of old people. A series of medicinal and edible compositions for improving cognitive and memory function decline of old people are developed. The composition disclosed by the invention has a good protective effect in delaying senile cognitive and memory function decline, can be applied to senile cognitive and memory function decline accompanied by age increase, enhances the activity of telomerase, and improves neurotransmitter homeostasis and brain health. Molecular mechanism research shows that the compound can reverse senescence of neuronal cells of hippocampus by activating key targets in a phosphatidylinositol-3-kinase / protein kinase B signal channel. The composition can be used for being developed into food and health care products for improving attention, learning ability, language ability and judgment, has safety and effectiveness, and has a very good application prospect.

The application discloses an antiepileptic preparation preparation method and application of a micro ribonucleic acid 145b targeting agent, and relates to the technical field of biological medicine. The method comprises the following steps: constructing a neuron-specific recombinant adeno-associated virus plasmid vector, wherein the vector comprises a neuron-specific promoter hSyn, a reporter gene, an enhancer, and a functional nucleic acid sequence for targeting and inhibiting micro ribonucleic acid 145b; using an adeno-associated virus packaging system to transfect the vector to a packaging cell for virus packaging; collecting a lysis solution and separating out a recombinant adeno-associated virus particle through a purification process; and resuspending the virus particle to obtain a preparation. The application specifically down-regulates the miR-145b level in hippocampal neurons, releases the inhibition of the Kcnq3 potassium ion channel, further up-regulates the Kcnq3 expression, restores the M current, and reduces the neuron excitability from a molecular mechanism.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The application belongs to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine supramolecular nanoparticle, which is prepared from Uncaria as a raw medicinal material, is extracted by heating reflux with 68-72% ethanol, is filtered, and is dried after being dialyzed after being dispersed in pure water, centrifuged, resuspended, and centrifuged again. The traditional Chinese medicine supramolecular nanoparticle has uniform particle size, a narrow particle size distribution, and high stability. The nanoparticle has obvious anti-nerve oxidation and obvious nerve protection effects according to in-vitro cell activity detection. The nanoparticle has good in-vivo nerve protection effect, can improve memory impairment and cognitive impairment, and can prevent hippocampal neuron reduction. Compared with Uncaria effective parts, the effective administration dose of the traditional Chinese medicine supramolecular nanoparticle is obviously reduced. The application also discloses a use of the traditional Chinese medicine supramolecular nanoparticle in preparation of a medicine for treating nervous system diseases.

The invention discloses a traditional Chinese medicine composition for improving hypertension left ventricular hypertrophy with depression and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from nine medicinal materials including lignum dalbergiae odoriferae, radix stephaniae tetrandrae, radix rehmanniae, radix angelicae sinensis, radix paeoniae rubra, rhizoma chuanxiong, rhizoma cyperi, radix puerariae and radix paeoniae alba. Experimental research proves that the composition can effectively reduce the blood pressure of spontaneous hypertension rats, reverse left ventricular hypertrophy and remarkably improve depression-like behaviors of the rats. The action mechanism relates to cooperation of multiple components, multiple targets and multiple pathways, and comprises adjustment of eNOS / NO pathways, improvement of endothelial functions, inhibition of release of inflammatory factors (TNF-alpha, IL-1beta and IL-6), reduction of oxidative stress (NOX4), inhibition of hippocampal neuron apoptosis and the like, so that the integrated curative effect of treating both heart and brain is achieved. The composition provides a safe and effective traditional Chinese medicine new choice for treating hypertension combined with left ventricular hypertrophy and depression.

The invention discloses an application of Naozhenning granules in preparation of drugs for inhibiting cGAS-STING pathways, and belongs to the technical field of modernization of traditional Chinese medicine, systematic in-vitro experiments prove that Naozhenning drug-containing serum can significantly inhibit excessive activation of cGAS-STING signal pathways in LPS-induced BV2 microglial cells and HT22 hippocampal neuronal cells, and can inhibit the cGAS-STING signal pathways in LPS-induced BV2 microglial cells and HT22 hippocampal neuronal cells. Specifically, the expression of proteins and mRNA of cGAS, STING and IRF3 is down-regulated, and the release of mtDNA is reduced, so that the polarization of microglial cells M1 is inhibited, the levels of proinflammatory factors such as IL-18, TNF-alpha and IFN-gamma are reduced, and the survival and proliferation of cells are promoted; particularly, it is found that the Naozhenning granules and the STING inhibitor SN-011 have a synergistic effect, and a brand new scientific basis and an application direction are provided for the Naozhenning granules in preparation of drugs for treating cGAS-STING pathway related nervous system diseases such as post-concussion syndromes.

This invention discloses the application of a natural isoflavone compound in the preparation of drugs for the prevention or treatment of depression. The natural isoflavone compound is hematoxylin A, a derivative of hematoxylin A, or a pharmaceutically acceptable salt of hematoxylin A. Hematoxylin A can effectively reduce oxidative damage to HT22 neurons in the hippocampus induced by glutamate and corticosterone, and can significantly improve the behavioral performance of mice in a chronic restraint stress depression model, exhibiting clear antidepressant activity. Hematoxylin A has a well-defined structure and good safety profile, showing promising application prospects in the development of antidepressant drugs.

Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer's disease (AD) and of the APP / PS1 mouse model of AD. They identified specific binding domains involved in the direct interaction between A0o and VEGF and engineered a peptide that blocks this interaction. The designed peptide binds to Aβ oligomers with high affinity and inhibits the process of Aβ self-aggregation, leading to the blockade of fibrillar aggregation. Furthermore, the peptide prevents soluble Aβ-derived toxins to target synapses in hippocampal neuron cultures and restores long-term potentiation in the hippocampus of the APP / PS1 mouse model of Alzheimer's disease. Thus, these findings have broad implications for preventing and treating diseases with Aβ neurotoxicity such as Alzheimer's disease. Accordingly, the invention relates to a peptide comprising the amino acid sequence KRKKSRYKSWSVYVG (SEQ ID NO: 1).